Back to top
more

Crinetics Pharmaceuticals (CRNX)

(Real Time Quote from BATS)

$60.00 USD

60.00
217,779

+0.19 (0.32%)

Updated Nov 8, 2024 02:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -7.14% and 6.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -0.66% and 7.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -9.30% and 70.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 72.73% and 59.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline

by Zacks Equity Research

Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

by Zacks Equity Research

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals

by Zacks Equity Research

Crinetics (CRNX) stock rises after achieving goals in the second late-stage study evaluating paltusotine in patients with acromegaly who are treatment-naive or not currently receiving medical therapy.

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

by Zacks Equity Research

Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Xencor (XNCR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xencor (XNCR) delivered earnings and revenue surprises of -186.11% and 68.25%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 0.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?

by Zacks Equity Research

Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 56.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AVROBIO, Inc. (AVRO) and Crinetics Pharmaceuticals, Inc. (CRNX) have performed compared to their sector so far this year.

Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 55.5% upside potential for Crinetics Pharmaceuticals, Inc. (CRNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

by Zacks Equity Research

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -35.29% and 15.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -3.66% and 325.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of 0% and 54.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -30.65% and 75.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?